Elevar Therapeutics

OverviewSuggest Edit

Elevar Therapeutics (previously known as LSK BioPharma) is a pharmaceutical company. It specializes in the clinical development of therapies for unmet medical needs in cancer. It develops two proprietary drug candidates: rivoceranib (Apatinib), a VEGFR-2 inhibitor, which dealing with a variety of solid tumors and a BTK/JAK3 inhibitor with the potential to treat hematologic malignancies and rheumatoid arthritis as an immunosuppressive agent.

TypePrivate
Founded2005
HQSouth San Francisco, CA, US
Websiteelevartherapeutics.com

Latest Updates

Employees (est.) (Sept 2021)46(+5%)
Cybersecurity ratingBMore

Key People/Management at Elevar Therapeutics

Kate McKinley

Kate McKinley

Chief Commercial Officer
Soo Whan Choi

Soo Whan Choi

Director
Yang Gon Jin

Yang Gon Jin

Chief Executive Officer, Director
Anthony Severini

Anthony Severini

Chief Financial Officer
Dong Gun Kim

Dong Gun Kim

Chief Strategy Officer
Show more

Elevar Therapeutics Office Locations

Elevar Therapeutics has offices in South San Francisco, Salt Lake City and Dublin
South San Francisco, CA, US (HQ)
400 Oyster Point Blvd #214
Salt Lake City, UT, US
2825 East Cottonwood Parkway Cottonwood Heights, Suite 500
Dublin, IE
Northside
Show all (4)

Elevar Therapeutics Financials and Metrics

Summary Metrics

Founding Date

2005

Elevar Therapeutics total Funding

$20 m

Elevar Therapeutics latest funding size

$20 m

Time since last funding

3 years ago
Elevar Therapeutics's latest funding round in July 2018 was reported to be $20 m. In total, Elevar Therapeutics has raised $20 m
Show all financial metrics

Elevar Therapeutics Cybersecurity Score

Cybersecurity ratingPremium dataset

B

88/100

SecurityScorecard logo

Elevar Therapeutics Online and Social Media Presence

Embed Graph

Elevar Therapeutics News and Updates

Elevar Therapeutics Announce New Data Highlighting Patient Burden and Unmet Needs Associated with Cremophor-Based Cancer Treatments

SALT LAKE CITY, May 18, 2021 /PRNewswire/ -- Elevar Therapeutics, Inc. ("Elevar"), a fully integrated biopharmaceutical company built on the promise of elevating treatment experiences and outcomes for patients who have limited or inadequate therapeutic options, today announced the...

Elevar Therapeutics Announces Licensing Agreement with Inceptua Group for Commercialization of Apealea® (Paclitaxel Micellar) in Europe

SALT LAKE CITY, Dec. 28, 2020 /PRNewswire/ -- Elevar Therapeutics, Inc. ("Elevar"), a fully integrated biopharmaceutical company built on the promise of elevating treatment experiences and outcomes for patients who have limited or inadequate therapeutic options, today announced that it...

Elevar Therapeutics Acquires Global Rights to European Approved Apealea® from Oasmia Pharmaceutical

SALT LAKE CITY, March 25, 2020 /PRNewswire/ -- Elevar Therapeutics, Inc., a fast-growing biopharmaceutical company focused on promising therapies for unmet medical needs in cancer, announced today an agreement with Swedish-based Oasmia Pharmaceutical AP to obtain global rights for...

Elevar Therapeutics Blogs

Elevar Therapeutics Announces CEO Transition and New Board Appointment

SALT LAKE CITY, USA., July 20, 2021 — Elevar Therapeutics, Inc. (“Elevar”), a fully integrated biopharmaceutical company built on the promise of elevating treatment experiences and outcomes for patients who have limited or inadequate therapeutic options, today announced that the Board of Directors h…

Elevar Therapeutics Announces New Appointments to Strengthen its Executive and Senior Leadership Teams

SALT LAKE CITY, USA., July 8, 2021 — Elevar Therapeutics, Inc. (“Elevar”), a fully integrated biopharmaceutical company built on the promise of elevating treatment experiences and outcomes for patients who have limited or inadequate therapeutic options, today announced the expansion of its executive…

Elevar Therapeutics Announces Orphan Drug Designation for Rivoceranib (Apatinib) for the Treatment of Adenoid Cystic Carcinoma (ACC)

SALT LAKE CITY, USA., February 8, 2021 — Elevar Therapeutics, Inc. (“Elevar”), a fully integrated biopharmaceutical company built on the promise of elevating treatment experiences and outcomes for patients who have limited or inadequate therapeutic options, today announced that the U.S. Food and Dru…

Elevar Therapeutics Announces Promotion of Mark Gelder, M.D. to Chief Medical Officer

SALT LAKE CITY, USA., January 12, 2021 — Elevar Therapeutics, Inc. (“Elevar”), a fully integrated biopharmaceutical company built on the promise of elevating treatment experiences and outcomes for patients who have limited or inadequate therapeutic options, announced today that Mark Gelder, M.D., ha…

Elevar Therapeutics Appoints Gus Aromin as Vice President of Regulatory Affairs

SALT LAKE CITY, USA., November 30, 2020 — Elevar Therapeutics, Inc. (“Elevar”), a fully integrated biopharmaceutical company built on the promise of elevating treatment experiences and outcomes for patients who have limited or inadequate therapeutic options, announced today that Gus Aromin has been …

Elevar Therapeutics Presents Safety and Efficacy Results of Rivoceranib (apatinib) in Combination with Nivolumab at the 2020 Connective Tissue Oncology Society (CTOS) Annual Meeting

SALT LAKE CITY, USA., November 19, 2020 — Elevar Therapeutics, Inc. (“Elevar”), a fully integrated biopharmaceutical company built on the promise of elevating treatment experiences and outcomes for patients who have limited or inadequate therapeutic options, today announced new clinical results from…
Show more

Elevar Therapeutics Frequently Asked Questions

  • When was Elevar Therapeutics founded?

    Elevar Therapeutics was founded in 2005.

  • Who are Elevar Therapeutics key executives?

    Elevar Therapeutics's key executives are Kate McKinley, Soo Whan Choi and Yang Gon Jin.

  • How many employees does Elevar Therapeutics have?

    Elevar Therapeutics has 46 employees.

  • Who are Elevar Therapeutics competitors?

    Competitors of Elevar Therapeutics include DAVA Oncology, OBI Pharma and Providence Therapeutics.

  • Where is Elevar Therapeutics headquarters?

    Elevar Therapeutics headquarters is located at 400 Oyster Point Blvd #214, South San Francisco.

  • Where are Elevar Therapeutics offices?

    Elevar Therapeutics has offices in South San Francisco, Salt Lake City and Dublin.

  • How many offices does Elevar Therapeutics have?

    Elevar Therapeutics has 4 offices.